Here are some excerpts from Dexcom’s most recent earnings call as posted on SeekingAlpha.com that I found interesting. These are specific to Dexcom’s cloud based platforms and the elimination of regular fingersticking, both areas of focus in development for G5 and G6 and having pending applications to the FDA. There was also reference to studies showing the accuracy of G4 as superior to Enlite, particularly in hypoglycemia. There was much more to the call including discussion of the financial impact of pediatric approval as well as Terry Gregg’s future with Dexcom, and I invite you to read the transcript in full at SeekingAlpha.com.
Terry Gregg, CEO
…our G4 PLATINUM sensor is significantly more accurate than Medtronic’s Enlite sensor. At this time most investors are aware of the work by Boston University where Dr. Steven Russell shared comparative data from patients simultaneously wearing the G4 PLATINUM and Medtronic’s Enlite with reported MARD of 10.8% for the G4 PLATINUM and 17.9% for the Enlite.
From the question and answer section:
…And then last question is you mentioned that on the progress with G5 and G6 anything in particular on the timing of those or when we might see a regulatory submission or studies? Thanks.
Kevin Sayer – President and Chief Operating Officer
We run early phase studies on our technologies before we go to publication we are running early phase studies on several different versions of these products in the pipeline now. But as far as timing when I need to get share approved first and that is really our first foray into the Gen5 market that will be our first cloud-based mobile application where you can share your data with others.
I think once we get that approval that will trigger a lot of efforts and a lot of thoughts on our partners to how we think accelerate things and how fast we can go. So now those product lines are both in pretty heavy development right now.
…can you separate out the specifics of G5 like what exactly will be the benefit G5 over G4 and then the same for G6?
Kevin Sayer, President and COO
G5 is going to be focused largely on connectivity, mobility and convenience. And it will come out more than likely as a series of launches rather than one big launch with the end goal of G5 being a simplified application system at the end, combined with connectivity to a phone in addition to be in connected to your receiver and cloud-based data. We’ll go there in a series of steps.
That system will use the Gen4 sensors currently configure but with new algorithms that we’ve developed over the course of the past few years that will improve accuracy and reliability.
With respect to the Gen6 system that’s our first step towards doing a couple of three things, culminating some of the calibrations, getting the replacement claim or dosing claim so you can dose insulin and then ultimately eliminating finger sticks altogether.
5 Replies to “#Dexcom Investor Call #CGM Q4 2013”
Thanks for the update! What about making the sensor/transmitter smaller? Did they mention anything?
It sounded like there would be no change to that. If I remember correctly, it mentioned that G5 will be compatible with current sensors. The changes would be in the algorithms and the cloud sharing capability.
I’d be willing to keep the slightly bulkier transmitter for better algorithms and cloud sharing capability for sure. Thanks for sharing the updates.
Thanks for this info Lorraine!
I just ordered my new Dexcom unit on my new insurance (transmitter at 10 months feels like it is on borrowed time). I am excited for the future of the company and their technology.
Stacey D. I agree with you but.. I would like both to happen!! Am I asking too much? Maybe but last year I think they mentioned something about G6 designing it from scratch and having the opportunity of making the transmiiter/sensor smaller.
Comments are closed.